{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:43:22Z","timestamp":1762865002689,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016060","name":"Stichting De Cock-Hadders","doi-asserted-by":"publisher","award":["2022-80"],"award-info":[{"award-number":["2022-80"]}],"id":[{"id":"10.13039\/100016060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001721","name":"Rijksuniversiteit Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.rpth.2023.102217","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T07:28:07Z","timestamp":1696922887000},"page":"102217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patients with metabolic dysfunction\u2013associated steatotic liver disease have preserved in\u00a0vitro responses to antiplatelet drugs"],"prefix":"10.1016","volume":"7","author":[{"given":"Bente P.","family":"van den Boom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 P.","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle","family":"Adelmeijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Blokzijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ton","family":"Lisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2023.102217_bib1","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2023.102217_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.rpth.2023.102217_bib3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.rpth.2023.102217_bib4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/obr.12407","article-title":"Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies","volume":"17","author":"Li","year":"2016","journal-title":"Obes Rev"},{"key":"10.1016\/j.rpth.2023.102217_bib5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.rpth.2023.102217_bib6","article-title":"Antithrombotic therapy in chronic liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding","volume":"10","author":"Chang","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.rpth.2023.102217_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2023.102217_bib8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/hep4.1254","article-title":"Use of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease","volume":"2","author":"Schwarzkopf","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.rpth.2023.102217_bib9","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rpth.2023.102217_bib10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13515","article-title":"Aspirin use is associated with lower indices of liver fibrosis among adults in the United States","volume":"43","author":"Jiang","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rpth.2023.102217_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2011.08.013","article-title":"Platelet function in patients with cirrhosis","volume":"56","author":"Lisman","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.rpth.2023.102217_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088390","article-title":"Differential in\u00a0vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis","volume":"9","author":"Potze","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2023.102217_bib13","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood.2020005319","article-title":"Anticoagulant activity of edoxaban in patients with cirrhosis","volume":"136","author":"Bos","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.102217_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2023.102217_bib15","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0049-3848(11)70017-2","article-title":"Resistance to anti-platelet agents","volume":"127","author":"Cattaneo","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2023.102217_bib16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/0091270009332433","article-title":"Clopidogrel resistance: pharmacokinetic or pharmacogenetic?","volume":"49","author":"Ford","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.rpth.2023.102217_bib17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2023.102217_bib18","first-page":"7211","article-title":"Resistance on the latest oral and intravenous P2Y12 ADP receptor blockers in patients with acute coronary syndromes: fact or myth?","volume":"11","author":"Bla\u0161ko","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.rpth.2023.102217_bib19","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rpth.2023.102217_bib20","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rpth.2023.102217_bib21","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.2337\/db07-0707","article-title":"The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study","volume":"56","author":"DiChiara","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.rpth.2023.102217_bib22","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A\u00a0comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"Lordkipanidz\u00e9","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2023.102217_bib23","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1093\/eurheartj\/ehn419","article-title":"Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients","volume":"29","author":"Lordkipanidz\u00e9","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2023.102217_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/09537104.2021.1983162","article-title":"\u201cTailored\u201d antiplatelet bridging therapy with cangrelor: moving toward personalized medicine","volume":"33","author":"Valenti","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.rpth.2023.102217_bib25","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2016.06.001","article-title":"Preserved hemostatic status in patients with non-alcoholic fatty liver disease","volume":"65","author":"Potze","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.rpth.2023.102217_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","article-title":"Clopidogrel pathway","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharmacogenet Genomics"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923004752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923004752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:28:11Z","timestamp":1762864091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037923004752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2475037923004752"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2023.102217","relation":{},"ISSN":["2475-0379"],"issn-type":[{"type":"print","value":"2475-0379"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with metabolic dysfunction\u2013associated steatotic liver disease have preserved in\u00a0vitro responses to antiplatelet drugs","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2023.102217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102217"}}